BOTHELL, Wash. & PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #ESMO–Izalontamab Brengitecan (Iza-Bren) Reduced Risk of Disease Progression or Death by 59% versus Chemotherapy in Patients with Advanced HR+/HER2-…

Subscribe to Our Newsletter

We keep your data private and share your data only with third parties that make this service possible. See our Privacy Policy for more information.